EUVIMEDEUVIMED entdecken
Fallbericht

Efficacy of CD38 ‐Targeted Therapy in Severe, Multi‐Agent Refractory Immune Thrombocytopenia: A Case Series

Parth S Patel iD, Stefan Farrugia, Jordan Nunnelee iD, Syeda Mina, Richard C Godby, Ronald Go iD, S Vincent Rajkumar iD

European Journal of Haematology · 2026-07 · 117 (1) · 279-282

DOI: 10.1111/ejh.70180 ↗

Kurz gefasst

Fallbericht in der Zeitschrift European Journal of Haematology, online erschienen am 02.04.2026. Verfasst von Parth S Patel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: ADP-ribosyl Cyclase 1, Antibodies, Monoclonal, Membrane Glycoproteins, Purpura, Thrombocytopenic, Idiopathic. Die Arbeit nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by antibody‐mediated platelet destruction, often driven by long‐lived plasma cells (LLPCs) resistant to conventional therapies. While most patients respond to corticosteroids and intravenous immunoglobulin (IVIG), a subset develops life‐threatening refractory disease. In this case series, we describe three patients aged 39, 85, and 58 with life‐threatening, multi‐agent refractory ITP and platelet nadirs < 2 × 10 9 /L who failed corticosteroids, IVIG, and thrombopoietin receptor agonists (TPO‐RAs). Following salvage therapy with daratumumab, a monoclonal antibody targeting CD38, all three patients achieved rapid hematologic recovery, with platelet count normalization within 1 week. This accelerated response allowed for urgent clinical stabilization, including safe anticoagulation and surgical intervention. The efficacy of daratumumab likely stems from a dual mechanism: the depletion of CD38+ LLPCs and the immediate modulation of Fc‐receptor‐mediated platelet clearance. These observations suggest that CD38‐targeted therapy can bypass traditional treatment resistance to achieve near‐immediate remission in high‐complexity, high‐risk clinical settings. While these results are compelling, prospective clinical trials are warranted to define the long‐term safety, durability, and optimal dosing of anti‐CD38 therapies in refractory ITP populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ADP-ribosyl Cyclase 1Antibodies, MonoclonalMembrane GlycoproteinsPurpura, Thrombocytopenic, IdiopathicAdultAgedHumansMaleMiddle AgedMolecular Targeted TherapyPlatelet CountSalvage TherapySeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

anti‐CD38 therapycombination therapydaratumumabimmune thrombocytopenia

Substanzen

ADP-ribosyl Cyclase 1Antibodies, MonoclonaldaratumumabMembrane Glycoproteins

Autor:innen und Institutionen

  • Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Hematology, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Parth S Patel, Jordan Nunnelee, Ronald Go, S Vincent Rajkumar

Zitieren

APA

Patel, P. S., Farrugia, S., Nunnelee, J., Mina, S., Godby, R. C., Go, R., & Rajkumar, S. V. (2026). Efficacy of CD38 ‐Targeted Therapy in Severe, Multi‐Agent Refractory Immune Thrombocytopenia: A Case Series. European Journal of Haematology, 117(1), 279-282. https://doi.org/10.1111/ejh.70180

Vancouver

Patel PS, Farrugia S, Nunnelee J, Mina S, Godby RC, Go R, et al. Efficacy of CD38 ‐Targeted Therapy in Severe, Multi‐Agent Refractory Immune Thrombocytopenia: A Case Series. European Journal of Haematology. 2026;117(1):279-282. doi:10.1111/ejh.70180

BibTeX
@article{Patel2026,
  author = {Patel, Parth S and Farrugia, Stefan and Nunnelee, Jordan and Mina, Syeda and Godby, Richard C and Go, Ronald and Rajkumar, S Vincent},
  title = {Efficacy of CD38 ‐Targeted Therapy in Severe, Multi‐Agent Refractory Immune Thrombocytopenia: A Case Series},
  journal = {European Journal of Haematology},
  year = {2026},
  volume = {117},
  number = {1},
  pages = {279--282},
  doi = {10.1111/ejh.70180}
}
Kostenlos starten →